What happened with YARW today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Yarrow Bioscience has focused on developing treatments for inflammatory and immune-mediated conditions. Its candidates include repibresib gel and the oral drug VYN202, using compounds exclusively licensed worldwide from Tay Therapeutics. The company has suspended and is winding down research and development in anticipation of a proposed merger, rather than continuing those programs as before.
Its current revenue comes entirely from LEO Pharma, which pays royalties on sales of Finacea foam under a licensing agreement. This income therefore depends on LEO Pharma’s sales of that product, not on sales of Yarrow’s experimental drugs.
Future operations depend heavily on whether the merger closes. Resuming drug development would require substantial additional funding and continued access to Tay’s licensed rights. VYN202 also faces an FDA trial restriction: the clinical hold has been partly lifted for female participants, but restarting treatment in male participants requires additional animal safety data.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Yarrow’s prospects hinge on clinical progress in the thyroid eye disease therapy licensed from GenSci and BET inhibitors licensed from Tay Therapeutics, rather than its small existing royalty stream from LEO Pharma.
Viridian Therapeutics competes with Yarrow’s licensed GenSci098 therapy by developing veligrotug and elegrobart for thyroid eye disease. Watch those programs’ clinical progress; Yarrow holds GenSci098’s rights outside China, while its phase 1 study was recruiting only in China as of January 2026.
Amgen competes with Yarrow in two treatment areas: it sells Tepezza for thyroid eye disease, an alternative to Yarrow’s licensed GenSci098 program, and Otezla for psoriasis.
Bristol Myers Squibb’s marketed oral psoriasis drug Sotyktu gives patients an existing alternative to Yarrow’s investigational oral VYN202. Its use in moderate-to-severe plaque psoriasis is the concrete competitive reference for VYN202’s initial proof-of-concept indication.
Takeda’s oral psoriasis candidates compete with Yarrow’s oral VYN202 program. For Yarrow holders, the relevant news is progress in those candidates, rather than sales of Takeda’s medicines for other diseases.
Johnson & Johnson competes with Yarrow’s VYN202 through psoriasis antibody medicines sold by Janssen and oral psoriasis candidates in development. Its oral-drug progress is particularly relevant to the treatment choices VYN202 would face.
AbbVie’s psoriasis medicines compete for the patients Yarrow aims to treat with VYN202, initially in moderate-to-severe plaque psoriasis. Watch pricing and sales-volume pressure in AbbVie’s immunology business for evidence of how crowded that treatment market is.
Eli Lilly competes with Yarrow’s VYN202 both through its marketed psoriasis medicine Taltz and through oral psoriasis candidates it is developing. Those oral candidates’ progress matters alongside Taltz as Yarrow tests VYN202 for moderate-to-severe plaque psoriasis.
Fed Interest Rate Decision
Yarrow earns interest on its cash, cash equivalents and marketable securities, so changes in rates can change the interest income supporting a business that otherwise reports operating losses.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher-than-expected rates can lift the yield Yarrow earns as cash and securities are reinvested or rates reset, increasing interest income; the effect depends on how quickly its balances reprice.
If it comes in below expectations
Lower-than-expected rates can reduce the yield Yarrow earns as cash and securities are reinvested or rates reset, lowering interest income that partly offsets its operating expenses.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb's report will show demand for its oral psoriasis drug Sotyktu, an existing treatment choice that Yarrow's VYN202 would face.
Look at Sotyktu sales trends and what the company says about use. Steady or rising demand would show that VYN202 faces an established oral alternative and must prove a meaningful difference to win patients; weakening demand could point to less pull for this oral option, but would not establish why or prove VYN202 would benefit.
Viridian Therapeutics, Inc. earningsVRDN
Viridian Therapeutics' report will show clinical progress for its thyroid eye disease candidates, which compete with GenSci098, licensed to Yarrow outside China.
Look for concrete clinical progress in veligrotug and elegrobart, alongside the fact that GenSci098's Phase 1 study was recruiting only in China. If Viridian advances its programs, competing options are moving forward while Yarrow's remains at an early stage; if they stall or hit setbacks, there is less near-term progress from this competitor, not proof that GenSci098 is ahead.
Yarrow Bioscience, Inc. earningsThis company
Yarrow Bioscience's royalty income is far below its research and administrative costs, and this report will show whether legacy income and lower spending are extending its cash runway.
Read royalties from the Finacea foam license alongside research and administrative costs and cash used in operations. Rising royalties with lower costs and cash use would show that legacy license income is still coming in as the wind-down slows the drain; falling royalties, or costs and cash use that stay high, would show the legacy business cannot fund operations, leaving the outlook dependent on completing the merger or finding other financing.
